ArticleMedicine2026
Red cell distribution width-to-albumin ratio and chronic kidney disease mortality in adults: A population-based NHANES 1999 to 2020 study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chronic kidney disease (CKD) is associated with systemic inflammation and malnutrition, but prognostic tools integrating these pathways are lacking. This study investigated the red cell distribution width-to-albumin ratio (RAR) as a novel biomarker for predicting all-cause mortality in CKD patients. We conducted a retrospective cohort study using National Health and Nutrition Examination Survey 1999 to 2020 data (N = 40,133, including 6795 CKD cases). The RAR was derived from standardized laboratory measurements. Multivariable Cox regression with restricted cubic splines analyzed mortality risk, complemented by time-dependent receiver operating characteristic analysis and mediation analysis. Models were adjusted for 38 covariates spanning demographics, comorbidities, and biochemical parameters. Among 40,133 participants (6795 CKD cases) from the National Health and Nutrition Examination Survey (1999-2020), elevated RAR was independently linked to higher mortality risk (adjusted hazard ratio [HR] = 2.12, 95% confidence interval [CI] = 1.66-2.70, P < .001). Restricted cubic spline analysis revealed a nonlinear association, with an optimal RAR threshold of 4.26. Patients with RAR > 4.26 faced a 70% increased mortality risk compared to those ≤4.26 (HR = 1.70, 95% CI = 1.58-1.82, P < .001). RAR surpassed red cell distribution width alone in predicting 1-year mortality (area under the curve = 0.59, 95% CI = 0.57-0.60 vs 0.55, 95% CI = 0.54-0.57; P < .001). Subgroup analyses showed stronger mortality associations in males (HR = 2.39, 95% CI = 1.96-2.69), alcohol consumers (HR = 2.60, 95% CI = 2.20-3.01), and nonanemic individuals (HR = 2.45, 95% CI = 2.10-2.85; P interaction < .05). The neutrophil-to-lymphocyte ratio mediated 7.89% of RAR's mortality risk. RAR, a composite biomarker reflecting erythrocyte instability and inflammation, provides robust prognostic value for CKD mortality. Its threshold (4.26) enables practical risk stratification, particularly in resource-limited settings. These findings support RAR's integration into clinical workflows to improve personalized CKD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.